Daily Brief Health Care: Wuxi Biologics, Actuate Therapeutics, Retension Pharmaceuticals, City Therapeutics, Decoy Therapeutics, First Wave BioPharma , Fujian Haixi Pharmaceuticals, Iambic Therapeutics and more

• WuXi Biologics Holdings (WBH) is looking to raise US$500m from a partial selldown of its stake in Wuxi Biologics (2269 HK).
• WBH had been continuously selling down its stake over the last few years.
• In this note, we will talk about the placement and run the deal through our ECM framework.

• Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company developing elraglusib for high impact, difficult to treat cancers by inhibiting GSK-3.
• Elraglusib’s Phase 2 study in mPDAC met its primary endpoint, demonstrating increased median overall survival and 12-month survival rate.
• The company has incurred significant operating losses and negative cash flows, requiring additional financing to fund operations.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Commercial Adoption Barriers: Novel vasodilators in hypertension face a high generic substitution barrier in primary care. To change prescriber behavior, therapies must demonstrate clear 24-hour ambulatory blood pressure monitoring (ABPM) control and target defined populations like uncontrolled or resistant hypertension where generic combinations have failed.
• RTN-001 Competitiveness: RTN-001 (formerly KD-027) is a tissue-targeted, once-daily PDE-5 inhibitor with a terminal half-life of 36 to 48 hours. In pilot Phase 2 trials, it achieved a sustained placebo-adjusted trough reduction of -5.92 mmHg SBP. This positions it competitively against approved endothelin receptor antagonists like aprocitentan (Tryvio), which only demonstrated a 3.8 mmHg SBP reduction, while avoiding the hyperkalemia risks of aldosterone synthase inhibitors.
• R&D Under-budgeting Risk: Retension’s IPO allocation of $10 million for Phase 3 clinical trials is highly unrealistic. A standard, registrational cardiorenal Phase 3 trial in uncontrolled hypertension requires 600 to 1,000 patients and will cost between $40 million and $60 million. The company’s post-IPO cash runway will be exhausted shortly after its Phase 2b data readout in the first half of 2027, necessitating a highly dilutive capital raise.

• City Therapeutics, Inc. (Nasdaq: CTY) is a clinical-stage biotechnology company pioneering next-generation RNA interference (RNAi) medicines engineered around proprietary ‘cleavage-inducing tiny RNA’ (cityRNA) trigger technology designed to overcome historical biodistribution and extra-hepatic delivery bottlenecks.
• The clinical pipeline is anchored by CITY-FXI, an investigational Phase 1 Factor XI-targeting siRNA therapeutic designed to prevent thromboembolic disorders while mitigating major hemorrhage risks, alongside near-term IND-track assets CITY-RBP4 for Stargardt disease and CITY-TFR2 for chronic anemia.
• Backed by premier RNAi founders, including founding Alnylam Chief Executive Dr. John Maraganore, CTY is supported by over $238.8 million in private capital, non-dilutive collaborations with Biogen (up to $1.0+ billion in total deal value) and Bausch + Lomb, and a September 2026 Nasdaq IPO filing to fund operations through Phase 2 clinical milestones.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Decoy Therapeutics Inc. is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT™ platform, aiming to build a robust portfolio.
• Decoy Therapeutics is a pre-clinical stage biotechnology company focused on peptide conjugate therapeutics, with a pipeline including D-MAV candidates and two legacy small molecule clinical candidates.
• The company has incurred recurring losses from operations since inception, has not generated product revenue, and faces substantial doubt about its ability to continue as a going concern.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• First Wave BioPharma (FWBI US) is a clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic oral therapeutics for gastrointestinal (GI) disorders, with primary developmental assets historically centered on adrulipase for exocrine pancreatic insufficiency (EPI) and latiglutenase for celiac disease.
• The company’s financial profile is defined by persistent operating losses, continuous cash burn, and de minimis commercial revenue ($0.036M in 2025; $0.086M in Q2 2026), creating severe liquidity pressure and reliance on continuous dilutive equity financings or strategic restructuring.
• Investment thesis remains fundamentally binary and high-risk: while latiglutenase targets an expansive addressable market with zero FDA-approved pharmacotherapies, realized shareholder value depends strictly on securing non-dilutive co-development partnerships, resolving debt overhangs, and navigating stringent registrational clinical trial requirements.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Imminent Pre-IPO Lockup Expiration: On October 20, 2026, the lockup on Fujian Haixi’s pre-IPO investors is set to expire, releasing half of the company’s total shares—valued at approximately US$800 million. Given the stock’s thin average daily volume of 154,000 shares, open-market liquidation is impossible; a block trade placement is the only viable exit route, likely demanding a steep 15% to 20% discount to clear.
• Dual-Track Financial Resilience: Unlike peer pre-revenue biotechs, Fujian Haixi is structurally profitable ahead of its main innovative launches. Its dual-track model leveraged 17 approved generic drugs (with four winning national Volume-Based Procurement bids, including Anbili and Ruiantuo) to generate RMB 467 million in revenue in 2024 and RMB 81.0 million in net profit for 1H 2026. This cash-generative segment buffers its oncology R&D cash burn.
• Divergent Pipeline Trajectories: The lead oncology asset, C019199 (an oral CSF-1R/DDR1/VEGFR2 inhibitor), recently initiated a Phase III trial for 3rd-line osteosarcoma (CTR20261818). While representing a fast regulatory pathway under NMPA Priority Review, its commercial TAM in China is highly constrained, making the potential out-licensing of the ophthalmic asset HXP056 (wet AMD, granted US FDA Fast Track in August 2026) the true valuation-unlocking catalyst for the company.

• AI Meets Biotech: Iambic combines proprietary AI with automated chemistry and biology to accelerate drug discovery through a continuous design–make–test platform.
• Strong Strategic Backing: ARK Invest and Duquesne have expressed interest in purchasing up to $60 million, providing a meaningful anchor for the IPO.
• Partnership Validation: Collaborations with AbbVie, Takeda, Lundbeck and others provide funding, data, expertise and external validation of Iambic’s technology.